OTC: HLUBF - H. Lundbeck A/S

Yield per half year: -34.42%
Dividend yield: +3.58%
Sector: Healthcare

Share chart H. Lundbeck A/S

Extended chart Simple chart
Financial Markets by TradingView

About H. Lundbeck A/S

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia.

more details
It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with FeetMe focusing on the use of sensor shoe soles. H. Lundbeck A/S also has a collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 3.58
Дивиденд ао 0.1445
Сайт https://www.lundbeck.com
Цена ао 4.35
Change price per day: 0% (3.7)
Change price per week: -8.3% (4.035)
Change price per month: -14.94% (4.35)
Change price per 3 month: -16.48% (4.43)
Change price per half year: -34.42% (5.642)
Change price per year: -11.06% (4.16)
Change price per year to date: -20% (4.625)
All parameters

Underestimation

Title Value Grade
P/S 0.1997 10
P/BV 1.27 9
P/E 1.4 10
EV/EBITDA 1.06 10
Total: 9.13

Efficiency

Title Value Grade
ROA, % 13.87 4
ROE, % 24.63 7
Total: 5.5

Dividends

Title Value Grade
Div yield, % 3.58 8.95
DSI 1 10
Total: 8.62

Debt

Title Value Grade
Debt/EBITDA 0.406 10
Total: 9.4

Growth impulse

Title Value Grade
Yield Revenue, % 41.6 6
Yield Ebitda, % 35.58 5
Yield EPS, % -54.74 0
Total: 4.2
More

Institutions Volume Share, %
Vanguard International Stock Index-Total Intl Stock Indx 766645 0.38
Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund 448123 0.23
iShares Core MSCI EAFE ETF 373578 0.19
DFA International Small Cap Value Portfolio 233923 0.12
iShares MSCI EAFE Small Cap ETF 208316 0.1
Vanguard Intl Equity Index Fds-FTSE All World ex U.S. Index Fund 124308 0.06
Vanguard International Stock Index-Vanguard European Stock Index 124066 0.06
iShares Core MSCI Total International Stock ETF 96483 0.05
Dimensional ETF Tr-Dimensional International Small Cap Value ETF 80813 0.04
iShares MSCI Denmark ETF 77939 0.04



Head Job title Payment Year of birth
Mr. Joerg Hornstein CFO & Executive VP of Corporate Functions 1.23M 1977 (48 years)
Mr. Lars Bang Executive Vice President of Product Development & Supply 1.14M 1962 (63 years)
Dr. Per Johan Luthman Executive Vice President of Research & Development 1.27M 1959 (66 years)
Mr. Charl van Zyl President & CEO 5.34M 1967 (58 years)
Dr. Tarek Samad Ph.D. Senior VP & Head of Research N/A
Mr. Palle Holm Olesen Chief Specialist & VP of Investor Relations N/A
Mr. Ole Chrintz Senior Vice President of International Markets N/A 1958 (67 years)
Dr. Rupert Sandbrink M.D., Ph.D. Senior VP & Head of Clinical Development N/A 1964 (61 year)
Ms. Tine Ostergaard Hansen Senior Vice President of Corporate Communications & Public Affairs N/A 1975 (50 years)
Ms. Dianne Holto Executive Vice President of People & Culture 1973 (52 years)

Address: Denmark, Valby, Ottiliavej 9 - open in Google maps, open in Yandex maps
Website: https://www.lundbeck.com